Editas Medicine, Inc.

EDIT

$75.92

+100.84% (1 year change)

Avg closing price

Price range

Market Cap

$4.01 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$62.8 Million

Total revenue in the last quarter.

Net Income

$7.82 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$1.62

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-44.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$8.99 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Editas Medicine, Inc.

News

Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson Sells 1,568 Shares of Stock

Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson Sells 1,568 Shares of Stock

Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 1,568 shares of Editas Medicine stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average pri...

Watchlist News Watchlist News, 1 day ago
Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy

Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy

Editas Medicine has received the FDA’s blessing to enter the clinic with its first ex vivo cell therapy — but it will do so without CSO Charles Albright, who is leaving his post for the same gig at...

Endpoints News Endpoints News, 4 days ago
Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells, Can Industry Giants take advantage of this Advancement? | Key PLayers: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences

Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells, Can Industry Giants take advantage of this Advancement? | Key PLayers: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences

Clusters of regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) is an innovative genome editing tool that has recently changed the field of human ge...

OpenPR OpenPR, 8 days ago